UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K	

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2018

LANTHEUS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-36569
(State or other jurisdiction (Commission

(Commission File Number) 35-2318913 (IRS Employer Identification No.)

331 Treble Cove Road, North Billerica, MA (Address of principal executive offices)

of incorporation)

01862 (Zip Code)

Registrant's telephone number, including area code: (978) 671-8001

Not Applicable

(Former name or former address, if changed since last report.)

ollo	Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the owing provisions (see General Instruction A.2. below):
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) cate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) ule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \square

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \square

Item 2.02. Results of Operations and Financial Condition.

On October 30, 2018, Lantheus Holdings, Inc. (the "Company") announced via press release its financial results as of and for the three and nine months ended, September 30, 2018. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1*	Press release of Lantheus Holdings, Inc. dated October 30, 2018, entitled "Lantheus Holdings, Inc. Reports Third Quarter 2018
	Results"

* Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS HOLDINGS, INC.

By: /S/ Michael P. Duffy

Name: Michael P. Duffy

Title: General Counsel, Senior Vice President, Law and Public Policy, and Secretary

Date: October 30, 2018

EXHIBIT INDEX

Exhibit No.	Description
99.1*	Press release of Lantheus Holdings, Inc. dated October 30, 2018, entitled "Lantheus Holdings, Inc. Reports Third Quarter 2018
	Results"

* Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.



331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com

Lantheus Holdings, Inc. Reports Third Quarter 2018 Financial Results

- Worldwide revenues of \$88.9 million for the third quarter, an increase of 11.2% over the prior year period
- Net income for the third quarter of \$9.3 million, or \$0.24 per diluted share, an increase of 8.7% over the prior year period
- EBITDA of \$20.0 million and Adjusted EBITDA of \$26.1 million for the third quarter, an increase of 17.9% and 15.5% over the prior year period, respectively
- · Company reaffirms full-year revenue and updates Adjusted EBITDA guidance

NORTH BILLERICA, Mass., October 30, 2018 - Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its third quarter ended September 30, 2018.

The Company's worldwide revenues for the third quarter of 2018 totaled \$88.9 million, compared with \$79.9 million for the third quarter of 2017. Net income for the third quarter of 2018 totaled \$9.3 million, or \$0.24 per diluted share, compared with \$8.5 million, or \$0.22 per diluted share, for the third quarter of 2017. The Company's third quarter 2018 EBITDA was \$20.0 million, or 22.5% of revenues, and its Adjusted EBITDA was \$26.1 million, or 29.4% of revenues, as compared with 21.2%, and 28.3% of revenues for the third quarter of 2017, respectively.

"We delivered double-digit growth in both DEFINITY and TechneLite in the third quarter," said Mary Anne Heino, President and CEO of Lantheus. "We continue to leverage our portfolio of products and capabilities to optimize growth and ensure the flexibility to respond to opportunities. As we consider investment strategies to expand and diversify our business, this robust financial performance further strengthens our balance sheet and ability to execute on initiatives."

Outlook

The Company reaffirms its full-year 2018 worldwide revenue guidance range of \$337 million to \$342 million. The Company has increased its full-year 2018 guidance range for Adjusted EBITDA, as described in the GAAP to non-GAAP reconciliation provided later in this release, to \$90 million to \$93 million from previous guidance of \$85 million to \$90 million, a margin of 26.3% to 27.6% of anticipated worldwide revenues.

The Company's guidance for worldwide revenues and Adjusted EBITDA are forward-looking statements. They are subject to various risks and uncertainties that could cause the Company's actual results to differ materially from guidance. Forward-looking statements are not predictions of the Company's actual performance. See the cautionary information about forward-looking statements in the "Safe-Harbor Statement" section of this press release.

Internet Posting of Information

The Company routinely posts information that may be important to investors in the "Investors" section of its website at http://www.lantheus.com/. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.

Conference Call and Webcast

As previously announced, the Company will host a conference call starting at 4:30 p.m. Eastern Time today. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 8386986. A live audio webcast of the call also will be available in the Investors section of the Company's website at www.lantheus.com.

A replay of the audio webcast will be available in the Investors section of our website at www.lantheus.com approximately two hours after completion of the call and will be archived for 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as revenues excluding the impact of foreign currency; adjusted operating income; adjusted net income and its line components; EBITDA; Adjusted EBITDA; adjusted net income per share - diluted; and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. The measures may exclude such items which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company's reported results of operations for a period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

This press release includes forward-looking non-GAAP guidance for 2018 Adjusted EBITDA. No reconciliation of this forward-looking non-GAAP guidance was included in this press release because, due to the high variability and difficulty in making accurate forecasts and projections of some of the excluded information and the fact that some of the excluded information is not readily ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measure without unreasonable efforts.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains "forward-looking statements" as defined under U.S. federal securities laws, including statements about our 2018 outlook. Forward-looking statements may be identified by their use of terms such as anticipate, believe, confident, could, estimate, expect, intend, may, plan, predict, project, target, will and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Contact

Meara Murphy 978-671-8508 Director, Investor Relations and Corporate Communications Lantheus Holdings, Inc.

- Tables Follow -

Page 3 of 10

Consolidated Statements of Operations

(in thousands, except per share data - unaudited)

		Three Months Ended September 30,					Nine Months Ended September 30,			
		2018		2017		2018		2017		
Revenues	\$	88,900	\$	79,941	\$	257,103	\$	250,137		
Cost of goods sold		44,015		41,414		126,063		125,901		
Gross profit		44,885		38,527		131,040		124,236		
Operating expenses										
Sales and marketing		10,478		10,075		33,248		31,892		
General and administrative		13,609		12,076		37,727		35,549		
Research and development		4,316		3,554		12,520		14,149		
Total operating expenses		28,403		25,705		83,495		81,590		
Operating income		16,482		12,822		47,545		42,646		
Interest expense		4,446		4,442		12,794		14,147		
Loss on extinguishment of debt		_		_		_		2,161		
Other income		(799)		(908)		(2,055)		(2,037)		
Income before income taxes		12,835		9,288		36,806		28,375		
Income tax expense		3,566		762		9,581		2,116		
Net income	\$	9,269	\$	8,526	\$	27,225	\$	26,259		
Net income per common share:										
Basic	\$	0.24	\$	0.23	\$	0.71	\$	0.71		
Diluted	\$	0.24	\$	0.22	\$	0.69	\$	0.67		
Weighted-average common shares outstanding:										
Basic		38,342		37,393		38,155		37,174		
Diluted		39,402		39,121		39,467		38,971		
	·		_		_		_			

Consolidated Segment Revenues Analysis

(in thousands – unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

	осристост 50,						
		2018	2017	Change %	2018	2017	Change %
<u>United States</u>							
DEFINITY	\$	42,472	\$ 36,901	15.1 %	\$ 131,081	\$ 113,035	16.0 %
TechneLite		19,374	22,621	(14.4)%	56,780	69,150	(17.9)%
Xenon		7,239	7,726	(6.3)%	22,805	23,709	(3.8)%
Other		1,170	2,331	(49.8)%	5,163	12,812	(59.7)%
Total United States		70,255	69,579	1.0 %	215,829	218,706	(1.3)%
<u>International</u>							
DEFINITY		1,283	828	55.0 %	3,427	2,534	35.2 %
TechneLite		11,244	3,735	201.0 %	18,711	10,750	74.1 %
Xenon		_	_	—%	_	4	(100.0)%
Other		6,118	5,799	5.5 %	19,136	18,143	5.5 %
Total International		18,645	 10,362	79.9 %	41,274	31,431	31.3 %
Worldwide							
DEFINITY		43,755	37,729	16.0 %	134,508	115,569	16.4 %
TechneLite		30,618	26,356	16.2 %	75,491	79,900	(5.5)%
Xenon		7,239	7,726	(6.3)%	22,805	23,713	(3.8)%
Other		7,288	8,130	(10.4)%	24,299	30,955	(21.5)%
Total Revenues	\$	88,900	\$ 79,941	11.2 %	\$ 257,103	\$ 250,137	2.8 %

Reconciliation of GAAP to Non-GAAP Financial Measures

 $(in\ thousands-unaudited)$

	Three Months Ended September 30,						ths Ended ıber 30,		
		2018		2017		2018		2017	
Operating income	\$	16,482	\$	12,822	\$	47,545	\$	42,646	
Campus consolidation costs including depreciation		84		797		1,154		5,779	
Offering and other costs		_		73		_		602	
Non-recurring refinancing related fees		_		_		_		1,721	
Adjusted operating income	\$	16,566	\$	13,692	\$	48,699	\$	50,748	
Adjusted operating income, as a percentage of revenues		18.6%		17.1%		18.9%		20.3%	

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except per share data – unaudited)

	Three Months Ended September 30,						ths Ended iber 30,		
	_	2018	2017			2018		2017	
Net income	\$	9,269	\$	8,526	\$	27,225	\$	26,259	
Reconciling items impacting operating income:									
Campus consolidation costs including depreciation		84		797		1,154		5,779	
Offering and other costs		_		73		_		602	
Non-recurring refinancing related fees		_		_		_		1,721	
Reconciling items impacting non-operating expenses and income taxes:									
Loss on debt extinguishment and retirement costs		_		_		_		2,161	
Income tax effect of non-GAAP adjustments(a) (b)		(21)		(220)		(291)		(2,591)	
Adjusted net income	\$	9,332	\$	9,176	\$	28,088	\$	33,931	
Adjusted net income, as a percentage of revenues		10.5%		11.5%		10.9%	· <u></u>	13.6%	

	Three Months Ended September 30,					Nine Mon Septen		
	2018			2017		2018		2017
Net income per share - diluted	\$	0.24	\$	0.22	\$	0.69	\$	0.67
Reconciling items impacting operating income:								
Campus consolidation costs including depreciation		_		0.02		0.03		0.15
Offering and other costs		_		_		_		0.02
Non-recurring refinancing related fees		_		_		_		0.04
Reconciling items impacting non-operating expenses and income taxes:								
Loss on debt extinguishment and retirement costs		_		_		_		0.06
Tax effect of non-GAAP adjustments(a) (b)		_		(0.01)		(0.01)		(0.07)
Adjusted net income per share - diluted	\$	0.24	\$	0.23	\$	0.71	\$	0.87
Weighted-average common shares outstanding - diluted		39,402		39,121		39,467		38,971

⁽a) The income tax effect of the adjustments between GAAP net income and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

⁽b) During the fourth quarter of 2017, we released the valuation allowance previously recorded against our domestic net deferred tax assets. As a result, we included the tax effect of non-GAAP adjustments starting in the fourth quarter of 2017. Presentation of 2017 Adjusted Net Income has been modified to allow better go-forward comparability by including the tax effect of non-GAAP reconciling items.

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands – unaudited)

	Three Moi Septen	 	Nine Mor Septer	
	2018	2017	 2018	2017
Net income	\$ 9,269	\$ 8,526	\$ 27,225	\$ 26,259
Interest expense, net	4,428	4,437	12,761	14,134
Income tax expense ^(a)	2,875	272	7,361	646
Depreciation	1,805	2,102	5,533	10,066
Amortization of intangible assets	1,650	1,646	5,011	4,953
EBITDA	20,027	16,983	57,891	56,058
Stock and incentive plan compensation	2,639	1,933	7,015	4,735
Asset write-off (b)	1,254	911	3,273	2,184
Severance and recruiting costs (c)	1,776	666	2,227	1,033
Offering and other costs (d)	_	73	_	602
Campus consolidation costs	84	408	1,154	1,101
Debt refinancing costs	_	_	_	1,721
Extinguishment of debt and debt retirement costs	_	_	_	2,161
New manufacturer costs (e)	334	1,639	1,301	3,616
Adjusted EBITDA	\$ 26,114	\$ 22,613	\$ 72,861	\$ 73,211
Adjusted EBITDA, as a percentage of revenues	29.4%	28.3%	28.3%	29.3%

- (a) Represents income tax expense, less tax indemnification income associated with Bristol-Myers Squibb.
- (b) Represents non-cash losses incurred associated with inventory and other write-offs of long-lived assets.
- (c) The amounts consist of severance and recruitment costs related to employees, executives and directors.
- (d) Represents offering costs incurred on behalf of certain shareholders pursuant to a registration rights agreement and other non-recurring costs.
- (e) Represents internal and external costs associated with establishing new manufacturing sources for our commercial and clinical candidate products.

Reconciliation of Free Cash Flow

(in thousands – unaudited)

	Three Moi Septen	 	Nine Mon Septen	-	
	 2018	2017	2018		2017
Net cash provided by operating activities	\$ 24,277	\$ 15,600	\$ 43,887	\$	41,691
Capital expenditures	(5,005)	(3,288)	(12,766)		(11,589)
Free cash flow	\$ 19,272	\$ 12,312	\$ 31,121	\$	30,102

Page 9 of 10

Condensed Consolidated Balance Sheets

(in thousands – unaudited)

	Sep	September 30, 2018		ecember 31, 2017
Assets				
Current assets				
Cash and cash equivalents	\$	104,584	\$	76,290
Accounts receivable, net		47,135		40,259
Inventory		34,572		26,080
Other current assets		4,669		5,221
Total current assets		190,960		147,850
Property, plant & equipment, net		99,407		92,999
Intangibles, net		9,727		11,798
Goodwill		15,714		15,714
Deferred tax assets, net		79,358		87,010
Other long-term assets		29,652		28,487
Total assets	\$	424,818	\$	383,858
Liabilities and stockholders' equity				
Current liabilities				
Current portion of long-term debt	\$	2,750	\$	2,750
Revolving line of credit		_		_
Accounts payable		20,363		17,464
Accrued expenses and other liabilities		31,464		26,536
Total current liabilities		54,577		46,750
Asset retirement obligations		11,282		10,412
Long-term debt, net		264,130		265,393
Other long-term liabilities		39,321		38,012
Total liabilities		369,310		360,567
Total stockholders' equity		55,508		23,291
Total liabilities and stockholders' equity	\$	424,818	\$	383,858

###